154 related articles for article (PubMed ID: 36269850)
1. A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.
Kamal MV; Rao M; Damerla RR; Pai A; Sharan K; Palod A; Shetty PS; Usman N; Kumar NAN
Cancer Invest; 2023 Feb; 41(2):144-154. PubMed ID: 36269850
[TBL] [Abstract][Full Text] [Related]
2. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K
Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Patil VM; Noronha V; Joshi A; Dhumal S; Mahimkar M; Bhattacharjee A; Gota V; Pandey M; Menon N; Mahajan A; Sable N; Kumar S; Nawale K; Mukadam S; Solanki B; Das S; Simha V; Abraham G; Chandrasekharan A; Talreja V; DSouza H; Srinivas S; Kashyap L; Banavali S; Prabhash K
J Clin Oncol; 2019 Nov; 37(32):3032-3041. PubMed ID: 31539316
[TBL] [Abstract][Full Text] [Related]
5. Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity.
Patil VM; Noronha V; Joshi A; Abhyankar A; Menon N; Dhumal S; Prabhash K
Oral Oncol; 2020 Jun; 105():104673. PubMed ID: 32272385
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Head and Neck Cancer Patients Treated with Palliative Oral Metronomic Chemotherapy at a Tertiary Cancer Center in Kerala, India.
Nv V; Muttath G; Jones J; Shringarpure K; Duraisamy K; Deenathayalan VP; Rathi P
Gulf J Oncolog; 2020 May; 1(33):68-74. PubMed ID: 32476653
[TBL] [Abstract][Full Text] [Related]
7. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
Kina S; Kawabata-Iwakawa R; Miyamoto S; Arasaki A; Sunakawa H; Kinjo T
J Drug Target; 2021 Dec; 29(10):1118-1127. PubMed ID: 33979258
[TBL] [Abstract][Full Text] [Related]
8. Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers.
Patil VM; Noronha V; Joshi A; Agarwala V; Muddu V; Ramaswamy A; Chandrasekharan A; Dhumal S; Juvekar S; Arya A; Bhattacharjee A; Prabhash K
Indian J Cancer; 2017; 54(1):20-24. PubMed ID: 29199655
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy and radiation therapy of squamous cell carcinoma of the head and neck.
Condit PT; Levitt SH; Snow JB; Knox GS; Williams GR; Bogardus CR; Eaton BG
Trans Am Acad Ophthalmol Otolaryngol; 1966; 70(4):627-39. PubMed ID: 6001354
[No Abstract] [Full Text] [Related]
10. Role of metronomic therapy for advanced oral cancers and predictors of response: Multi-institutional feasibility study.
Sultania M; Imaduddin M; S V Deo S; Kar M; K Muduly D; Kumar S; Sharma A; Mishra A; K D Majumdar S; K Adhya A; K Parida D
Head Neck; 2022 Jan; 44(1):104-112. PubMed ID: 34708450
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
Patil VM; Noronha V; Menon N; Rai R; Bhattacharjee A; Singh A; Nawale K; Jogdhankar S; Tambe R; Dhumal S; Sawant R; Alone M; Karla D; Peelay Z; Pathak S; Balaji A; Kumar S; Purandare N; Agarwal A; Puranik A; Mahajan A; Janu A; Kumar Singh G; Mittal N; Yadav S; Banavali S; Prabhash K
J Clin Oncol; 2023 Jan; 41(2):222-232. PubMed ID: 36265101
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Kushwaha VS; Gupta S; Husain N; Khan H; Negi MP; Jamal N; Ghatak A
Cancer Biol Ther; 2015; 16(2):346-51. PubMed ID: 25756517
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
14. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Patil V; Noronha V; Krishna V; Joshi A; Prabhash K
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):388. PubMed ID: 23434353
[No Abstract] [Full Text] [Related]
15. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML
Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657
[TBL] [Abstract][Full Text] [Related]
16. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.
Patil V; Noronha V; Dhumal SB; Joshi A; Menon N; Bhattacharjee A; Kulkarni S; Ankathi SK; Mahajan A; Sable N; Nawale K; Bhelekar A; Mukadam S; Chandrasekharan A; Das S; Vallathol D; D'Souza H; Kumar A; Agrawal A; Khaddar S; Rathnasamy N; Shenoy R; Kashyap L; Rai RK; Abraham G; Saha S; Majumdar S; Karuvandan N; Simha V; Babu V; Elamarthi P; Rajpurohit A; Kumar KAP; Srikanth A; Ravind R; Banavali S; Prabhash K
Lancet Glob Health; 2020 Sep; 8(9):e1213-e1222. PubMed ID: 32827483
[TBL] [Abstract][Full Text] [Related]
17. EphA4 signaling is involved in the phenotype of well-differentiated oral squamous cell arcinoma with decreased tumor immunity.
Kina S; Kawabata-Iwakawa R; Miyamoto S; Kato T; Kina-Tanada M; Arasaki A
Eur J Pharmacol; 2023 Apr; 945():175611. PubMed ID: 36804938
[TBL] [Abstract][Full Text] [Related]
18. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
[TBL] [Abstract][Full Text] [Related]
19. Oral Squamous Cell Carcinoma Following Acute Methotrexate Toxicity in a Psoriasis Patient: A Causal Association or Mere Co-Incidence.
Choudhary R; Singh A; Chhabra N; Gupta AK
Curr Drug Saf; 2023; 18(4):580-583. PubMed ID: 36017826
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
